Company intelligence / Profile preview

Entrepreneurial Investment Partners

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

EIP Pharma was a clinical-stage biotechnology company focused on developing small-molecule therapeutics for neurodegenerative diseases. The company's lead program, neflamapimod, is an oral, brain-penetrant inhibitor of the p38 alpha MAPK enzyme, which plays a critical role in synaptic dysfunction. EIP Pharma primarily targeted dementia with Lewy bodies (DLB) and Alzheimer's disease, aiming to improve cognitive and motor functions by restoring synaptic health. In 2023, the company completed a reverse merger with Diffusion Pharmaceuticals to form CervoMed, continuing the development of its CNS pipeline.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Entrepreneurial Investment Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Entrepreneurial Investment Partners.

Explore the full profile